ELAN Q1 2024 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.2B-4.1% YoY

Gross Profit

$557M46.2% margin

Operating Income

$133M11.0% margin

Net Income

$32M2.7% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+16.4%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

-$22M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$14.0B

Total Liabilities

$8.0B

Stockholders' Equity

$6.1B

Cash & Equivalents

$345M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$1.3B	-4.1%
Gross Profit	$557M	$629M	-11.4%
Operating Income	$133M	$221M	-39.8%
Net Income	$32M	$103M	-68.9%

Revenue Segments

Pet Health

$639M37%

Farm Animal

$556M32%

Cattle

$244M14%

Poultry

$197M11%

Swine

$84M5%

Contract Manufacturing

$10M1%

Geographic Segments

Non-US

$674M56%

UNITED STATES

$531M44%